原先用于糖尿病的GLP-1药物现在被4 100万美国人用于减肥,推动饮食和食品工业趋势的重大变化。 GLP-1 drugs, originally for diabetes, are now used by 41 million Americans for weight loss, driving major shifts in diet and food industry trends.

GLP-1类药物,如Ozempic和Wegovy最初用于糖尿病,现在估计有4 100万美国人用于减肥和新陈代谢健康,近90%的成年人对新陈代谢的不健康驾驶需求。 GLP-1 drugs like Ozempic and Wegovy, originally for diabetes, are now used by an estimated 41 million Americans for weight loss and metabolic health, with nearly 90% of adults metabolically unhealthy driving demand. 超过100种临床试验正在探索其在心脏病、阿尔茨海默氏病和其他病症中的使用,而多效药则显示体重下降24%。 Over 100 clinical trials are exploring their use in heart disease, Alzheimer’s, and other conditions, while multi-agonist drugs show up to 24% weight loss. 新的投送方法和即将出台的通用版本可以改善获取途径。 New delivery methods and upcoming generic versions could improve access. 用户正在削减糖、酒精和加工食品,在甜点销售方面造成30亿美元的缺口,推动食品公司根据不断变化的消费者习惯制定更健康、个性化的选择。 Users are cutting sugar, alcohol, and processed foods, creating a $3 billion gap in dessert sales, pushing food companies to develop healthier, personalized options aligned with changing consumer habits.